250 related articles for article (PubMed ID: 19050056)
1. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.
Wesseling-Perry K; Pereira RC; Wang H; Elashoff RM; Sahney S; Gales B; Jüppner H; Salusky IB
J Clin Endocrinol Metab; 2009 Feb; 94(2):511-7. PubMed ID: 19050056
[TBL] [Abstract][Full Text] [Related]
2. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
3. [The relationship between advancement of secondary hyperparathyroidism and selected calcification parameters in peritoneal dialysis patients].
Janda K; Krzanowski M; Dumnicka P; Kuśnierz-Cabala B; Sułowicz W
Przegl Lek; 2012; 69(12):1241-5. PubMed ID: 23750431
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of FGF-23 measurement in dialysis patients.
Jongbloed F; Galassi A; Cozzolino M; Zietse R; Chiarelli G; Cusi D; Brancaccio D; Gallieni M
Clin Nephrol; 2011 Sep; 76(3):201-9. PubMed ID: 21888857
[TBL] [Abstract][Full Text] [Related]
5. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.
Nakanishi S; Kazama JJ; Nii-Kono T; Omori K; Yamashita T; Fukumoto S; Gejyo F; Shigematsu T; Fukagawa M
Kidney Int; 2005 Mar; 67(3):1171-8. PubMed ID: 15698459
[TBL] [Abstract][Full Text] [Related]
6. FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis.
Lima F; El-Husseini A; Monier-Faugere MC; David V; Mawad H; Quarles D; Malluche HH
Clin Nephrol; 2014 Nov; 82(5):287-95. PubMed ID: 25208316
[TBL] [Abstract][Full Text] [Related]
7. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?
Wesseling-Perry K; Tsai EW; Ettenger RB; Jüppner H; Salusky IB
Nephrol Dial Transplant; 2011 Nov; 26(11):3779-84. PubMed ID: 21441401
[TBL] [Abstract][Full Text] [Related]
8. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
Shigematsu T; Kazama JJ; Yamashita T; Fukumoto S; Hosoya T; Gejyo F; Fukagawa M
Am J Kidney Dis; 2004 Aug; 44(2):250-6. PubMed ID: 15264182
[TBL] [Abstract][Full Text] [Related]
9. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
Tanaka H; Hamano T; Fujii N; Tomida K; Matsui I; Mikami S; Nagasawa Y; Ito T; Moriyama T; Horio M; Imai E; Isaka Y; Rakugi H
Bone; 2009 Nov; 45(5):949-55. PubMed ID: 19631779
[TBL] [Abstract][Full Text] [Related]
10. Lower fibroblast growth factor 23 levels in young adults with Crohn disease as a possible secondary compensatory effect on the disturbance of bone and mineral metabolism.
Oikonomou KA; Orfanidou TI; Vlychou MK; Kapsoritakis AN; Tsezou A; Malizos KN; Potamianos SP
J Clin Densitom; 2014; 17(1):177-84. PubMed ID: 23623649
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
Evenepoel P; Meijers B; Viaene L; Bammens B; Claes K; Kuypers D; Vanderschueren D; Vanrenterghem Y
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
[TBL] [Abstract][Full Text] [Related]
13. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
[TBL] [Abstract][Full Text] [Related]
14. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.
Wetmore JB; Santos PW; Mahnken JD; Krebill R; Menard R; Gutta H; Quarles LD
J Clin Endocrinol Metab; 2011 Jan; 96(1):E57-64. PubMed ID: 20943782
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).
Wesseling-Perry K; Harkins GC; Wang HJ; Elashoff R; Gales B; Horwitz MJ; Stewart AF; Jüppner H; Salusky IB
J Clin Endocrinol Metab; 2010 Jun; 95(6):2772-80. PubMed ID: 20382692
[TBL] [Abstract][Full Text] [Related]
17. The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients.
Park SY; Jeong KH; Moon JY; Lee SH; Ihm CG; Rhee SY; Woo JT; Oh IH; Lee TW
Clin Exp Nephrol; 2010 Jun; 14(3):239-43. PubMed ID: 20376517
[TBL] [Abstract][Full Text] [Related]
18. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
19. [Biological activity of FGF-23 and pathophysiologic role in chronic kidney disease].
Yamashita T
Clin Calcium; 2004 May; 14(5):760-3. PubMed ID: 15577039
[TBL] [Abstract][Full Text] [Related]
20. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
Sato T; Tominaga Y; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Uchida K; Nakanishi S; Kazama JJ; Gejyo F; Yamashita T; Fukagawa M
Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
